Access to clinical trials — where new and often experimental treatments are tested — is, for many people, the only chance to escape a difficult medical situation in which standard therapies may no longer work. Unfortunately, more than 74,000 individuals have just lost access to such trials after the Trump administration sought cost savings at the National Institutes of Health (NIH).
An analysis by a Harvard research team revealed that some of the canceled studies focused on diseases of major public importance, including cancers, infections, and reproductive health. As a result of the interruptions, patients lost access to experimental therapies, regular monitoring, or continued research follow-ups.
The authors of the report highlight that abruptly halting studies is not only a scientific setback but also a breach of ethical standards for research involving human subjects. Trial participants may be deprived of the promised treatment or observation that had long been built into the study protocols.
Statistics also show that the most significant losses occurred in areas crucial to public health. Among the 383 clinical trials that lost funding, 31% involved cancer (118 trials), 25% infectious diseases (97 trials), 12.5% reproductive health (48 trials), and 12% mental health (47 trials).
The scale of the cuts raises concerns that political decisions may determine which medical studies continue and which do not — a trend that could undermine public trust in clinical research and reduce patients’ willingness to participate in future trials. After all, no one knows when their study might suddenly be shut down.